Submit your event on Fibroblast Cell Markers to be featured.
Fibroblast Cell MarkersWhat are Fibroblasts?Fibroblasts are cells of mesenchymal origin that are most commonly found in connective tissue. They serve to synthesize components of the extracellular matrix (ECM) and stroma, hence fibroblasts play an important role in cell maintenance and structural homeostasis. Connective tissue structural integrity is sustained by fibroblast secretion of ECM precursors, such as collagen I.
Bright-field microscopy image of verified fibroblast morphology from cells generated from skin-punch biopsy under 4x (left) and 20x (right) magnification. Image collected and cropped by from the following publication (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043099), licensed under a CC0 1.0 license. Fibroblast Cell MarkersFibroblasts are regarded as one of the more difficult cell types to identify given their heterogeneity. In addition to their location and typical spindle-like shape, fibroblasts have traditionally been identified through positive expression of the mesenchymal markers vimentin and PDGFR alpha. Since the late 1980s a few reported anti-fibroblast antibodies have been identified including TE-7, an antibody against thymic stroma, and 1B10, which is shown to react with human fibroblasts and cell lines, tissue macrophages, and peripheral blood monocytes.
Cell markers for fibroblast characterization and analysis are used in several research applications including immunohistochemistry (IHC), immunocytochemistry (ICC)/immunofluorescence(IF), flow cytometry, and western blot. Additionally, RNAscope® is a powerful tool allowing for visualization of fibroblast marker gene expression in situ. Common Fibroblast Markers:
*Marker is predominantly for activated fibroblasts rather than mature, quiescent fibroblasts. View Fibroblast Cell Marker Products
Fibroblast Cell Origin & PlasticityThe heterogeneity observed in fibroblasts function and lack of unique cellular markers is partially attributed to their multiple developmental origins. Primary fibroblasts arise from the primary mesenchyme during gastrulation. Further along in development, true mesenchyme generated from the mesoderm gives rise to mature, resident fibroblasts. Some studies have also suggested a hematopoietic stem cell origin for fibroblasts. Besides resident fibroblasts, the mesoderm also contributes to the development of other cell types including mesenchymal stem cells, epithelial cells, endothelial cells, adipocytes, and fibrocytes. The common embryonic origin with other cells of mesenchymal lineage contributes to cellular plasticity amongst these populations. This plasticity between fibroblasts and other cell types is generally observed in the context of injury, inflammation, and cancer or other pathologies. Epithelial cells can convert to fibroblasts through epithelial-to-mesenchymal transition (EMT), which is a hallmark of cancer. Furthermore, during wound healing, adipocytes have been shown to lose their lipid stores, migrate to the wound, and become fibroblasts. Overall, fibroblast plasticity is highest during embryonic and early development and decreases with aging. Fibroblast Cell Origin and Lineage PlasticityFibroblasts may be derived from a number of cell types through a variety of mechanisms including division and proliferation, transdifferentiation such as EMT or EndoMT, differentiation of precursors cells like mesenchymal stem cells or hematopoietic stem cells, and de-differentiation of mature cell types. Fibroblasts may originate from several cell types, including:
Cancer-Associated FibroblastsCancer-associated fibroblasts (CAFs) are a subgroup of activated fibroblasts that are found within the tumor microenvironment (TME). CAFs contribute to cancer progression, metastasis, and immune cell reprogramming by secretion of growth factors, cytokines and chemokines, interleukins, matrix metalloproteases (MMPs), and ECM deposition. Several mechanisms have been shown to activate normal, resident fibroblasts to become CAFs including:
While CAFs continue to express a number of common fibroblast biomarkers such as alpha-SMA, FSP1 (S100A4), and FAP, they are often upregulated, whereas PDGFR alpha is reduced. CAFs have also been shown to originate from and express markers from cells of other origins. For example, CAFs of endothelial cell origin express Podoplanin, of lymphocyte or dendritic cell origin express CD70, and of neutrophil origin express GPR77. Furthermore, CAFs can be grouped into different subsets based on their biomarker expression.
*CAFs expressing neutral biomarkers can be subdivided into two groups – myofibroblastic CAFs (myCAFs) (alpha-SMAhighIL-6low) or inflammatory CAFs (iCAFs) (alpha-SMAlowIL-6high). Similar to resident fibroblasts, heterogeneity persists within the CAF subgroup.
Practical Applications of FibroblastsFibroblasts are commonly cultured in the laboratory, both in primary fibroblast cell cultures and transformed cell lines. Given their accessibility, fibroblasts are often used in regenerative medicine. Fibroblasts are easily obtained from donor skin or hair biopsies and can be used as a direct source for cell therapy or easily reprogrammed into induced pluripotent stem cell (iPSCs). Subsequently, iPSCs can be used directly or can be genetically engineered, and differentiated into mature, tissue-specific cells for disease modeling. Learn More About the Applications of iPSCs Cell CultureCommonly, fibroblast cell lines are used as a feeder monolayer to support the survival and growth of other cell types. In general, feeder cells are adherent cells locked in a state of growth arrest that secrete growth factors into the media and provide cell-cell contact. Mouse embryonic fibroblasts (MEFs) and human dermal fibroblasts (HDFs) are two common types of feeder cells that support the culture of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).
Regenerative Medicine & Tissue EngineeringThe source of fibroblasts in regenerative medicine can be autologous (from the self) or allogeneic (from a donor). While use of autologous cells limits the risk of graft rejection, the process often is more time consuming and requires large-scale cell expansion, whereas harvested allogeneic cells can be banked, cryopreserved, and ready-to-use to treat multiple patients. In addition to iPSC-based regenerative medicine, dermal fibroblasts can be used in the clinic for wound repair in ulcers, burns, the treatment of fragility skin disorders, and reconstructive surgeries. Besides skin regeneration, fibroblasts can also be utilized for cardiac, liver, and bone and cartilage regeneration. Gene-corrected autologous or allogeneic fibroblasts can be either directly injected into the patient or grown on a scaffold and engrafted for transplantation. In scaffold-based skin tissue engineering, fibroblasts are mounted onto a synthetic matrix with the addition of growth factors, small molecules, and mechanical stimuli. The scaffold creates a microenvironment conducive to skin organization and generation of an engineered graft. Autologous fibroblast cell therapy for treatment of skin disorders. A skin biopsy is taken from the patient with a skin disorder (1), fibroblasts are isolated and characterized from the sample (2), and gene corrected (3). The fibroblast population is expanded (4) and can either be directly injected into the patient wound or transplanted via a skin graft from fibroblasts seeded onto a scaffold (5). Select ReferencesChang, Y., Li, H., & Guo, Z. (2014). Mesenchymal stem cell-like properties in fibroblasts. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 34(3), 703–714. https://doi.org/10.1159/000363035 Costa-Almeida, R., Soares, R., & Granja, P. L. (2018). Fibroblasts as maestros orchestrating tissue regeneration. Journal of tissue engineering and regenerative medicine, 12(1), 240–251. https://doi.org/10.1002/term.2405 Fernandes, I. R., Russo, F. B., Pignatari, G. C., Evangelinellis, M. M., Tavolari, S., Muotri, A. R., & Beltrão-Braga, P. C. (2016). Fibroblast sources: Where can we get them?. Cytotechnology, 68(2), 223–228. https://doi.org/10.1007/s10616-014-9771-7 Goodpaster, T., Legesse-Miller, A., Hameed, M. R., Aisner, S. C., Randolph-Habecker, J., & Coller, H. A. (2008). An immunohistochemical method for identifying fibroblasts in formalin-fixed, paraffin-embedded tissue. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 56(4), 347–358. https://doi.org/10.1369/jhc.7A7287.2007 Han, C., Liu, T., & Yin, R. (2020). Biomarkers for cancer-associated fibroblasts. Biomarker research, 8(1), 64. https://doi.org/10.1186/s40364-020-00245-w Llames, S., García-Pérez, E., Meana, Á., Larcher, F., & del Río, M. (2015). Feeder Layer Cell Actions and Applications. Tissue engineering. Part B, Reviews, 21(4), 345–353. https://doi.org/10.1089/ten.TEB.2014.0547 LeBleu, V. S., & Neilson, E. G. (2020). Origin and functional heterogeneity of fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(3), 3519–3536. https://doi.org/10.1096/fj.201903188R Mascharak, S., desJardins-Park, H. E., & Longaker, M. T. (2020). Fibroblast Heterogeneity in Wound Healing: Hurdles to Clinical Translation. Trends in molecular medicine, 26(12), 1101–1106. https://doi.org/10.1016/j.molmed.2020.07.008 Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S., & Letellier, E. (2020). In search of definitions: Cancer-associated fibroblasts and their markers. International journal of cancer, 146(4), 895–905. https://doi.org/10.1002/ijc.32193 Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., Ramirez, D. C., … Werb, Z. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nature reviews. Cancer, 20(3), 174–186. https://doi.org/10.1038/s41568-019-0238-1 Shams, F., Rahimpour, A., Vahidnezhad, H., Hosseinzadeh, S., Moravvej, H., Kazemi, B., Rajabibazl, M., Abdollahimajd, F., & Uitto, J. (2021). The utility of dermal fibroblasts in treatment of skin disorders: A paradigm of recessive dystrophic epidermolysis bullosa. Dermatologic therapy, 34(4), e15028. https://doi.org/10.1111/dth.15028 Vapniarsky, N., Arzi, B., Hu, J. C., Nolta, J. A., & Athanasiou, K. A. (2015). Concise Review: Human Dermis as an Autologous Source of Stem Cells for Tissue Engineering and Regenerative Medicine. Stem cells translational medicine, 4(10), 1187–1198. https://doi.org/10.5966/sctm.2015-0084 Wong, T., McGrath, J. A., & Navsaria, H. (2007). The role of fibroblasts in tissue engineering and regeneration. The British journal of dermatology, 156(6), 1149–1155. https://doi.org/10.1111/j.1365-2133.2007.07914.x |